{"id":11393,"date":"2020-01-06T01:28:51","date_gmt":"2020-01-06T01:28:51","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=11393"},"modified":"2022-08-04T03:06:44","modified_gmt":"2022-08-04T03:06:44","slug":"continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/","title":{"rendered":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &#038; Co"},"content":{"rendered":"<p>We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16 based on the following factors: (1) increasing our projected chance of success for PTX-200 in HTR breast cancer from 14% to 18%; (2) adjustment to base year; and (3) adjustment to exchange rate. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug&#8217;s potential commercial profile.<span class=\"c-message__edited_label\" dir=\"ltr\" aria-describedby=\"slack-kit-tooltip\">&nbsp;<\/span><\/p>\n<p>Click <a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2018\/03\/PTX_PTX-200-Continues-Its-Positive-Push-Forward-in-Breast-Cancer-Target-Upped-to-A0.20.pdf\">here<\/a> to read the full report (report\/PDF Download)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16 based on the following factors: (1) increasing our projected chance of success for PTX-200 in HTR breast cancer from 14% to 18%; (2) adjustment to base year; and (3) adjustment to exchange rate. Our valuation is based on our clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":27237,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,1],"tags":[29],"class_list":["post-11393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-news","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &amp; Co - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &amp; Co - PTX Therapeutics\" \/>\n<meta property=\"og:description\" content=\"We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16 based on the following factors: (1) increasing our projected chance of success for PTX-200 in HTR breast cancer from 14% to 18%; (2) adjustment to base year; and (3) adjustment to exchange rate. Our valuation is based on our clinical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-06T01:28:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-04T03:06:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"558\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &#038; Co\",\"datePublished\":\"2020-01-06T01:28:51+00:00\",\"dateModified\":\"2022-08-04T03:06:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\"},\"wordCount\":92,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Articles\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\",\"name\":\"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright & Co - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg\",\"datePublished\":\"2020-01-06T01:28:51+00:00\",\"dateModified\":\"2022-08-04T03:06:44+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg\",\"width\":960,\"height\":558},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &#038; Co\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright & Co - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright & Co - PTX Therapeutics","og_description":"We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16 based on the following factors: (1) increasing our projected chance of success for PTX-200 in HTR breast cancer from 14% to 18%; (2) adjustment to base year; and (3) adjustment to exchange rate. Our valuation is based on our clinical [&hellip;]","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/","og_site_name":"PTX Therapeutics","article_published_time":"2020-01-06T01:28:51+00:00","article_modified_time":"2022-08-04T03:06:44+00:00","og_image":[{"width":960,"height":558,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg","type":"image\/jpeg"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &#038; Co","datePublished":"2020-01-06T01:28:51+00:00","dateModified":"2022-08-04T03:06:44+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/"},"wordCount":92,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg","keywords":["Prescient Therapeutics"],"articleSection":["Articles","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/","name":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright & Co - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg","datePublished":"2020-01-06T01:28:51+00:00","dateModified":"2022-08-04T03:06:44+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2020\/01\/medical-procedures-3579029_960_720.jpg","width":960,"height":558},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/continues-its-positive-push-forward-in-breast-cancer-target-upped-to-a0-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"PTX Target Price Revision: Target Upped to A$0.20 \u2013 H.C Wainwright &#038; Co"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=11393"}],"version-history":[{"count":1,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11393\/revisions"}],"predecessor-version":[{"id":27236,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11393\/revisions\/27236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/27237"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=11393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=11393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=11393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}